News Releases

Date	Title and Summary	View
June 4, 2019	KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology – KVD900 Demonstrates Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity in a Phase 1 Study – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 4, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...	Additional Formats PDF Version
May 30, 2019	KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...	Additional Formats PDF Version
May 28, 2019	KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop – KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein Activity and is Well Tolerated for Potential Use as On-Demand Treatment for HAE – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical...	Additional Formats PDF Version
May 20, 2019	KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences – Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 20, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the...	Additional Formats PDF Version
April 30, 2019	KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 – Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the...	Additional Formats PDF Version
April 22, 2019	KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 22, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has...	Additional Formats PDF Version
April 3, 2019	KalVista Pharmaceuticals to Present at Needham Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 3, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...	Additional Formats PDF Version
March 27, 2019	KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 27, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the promotion of Ben...	Additional Formats PDF Version
March 14, 2019	KalVista Pharmaceuticals Reports Fiscal Third Quarter Results – Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosing in First-in-Human Trial – CAMBRIDGE, Mass....	Additional Formats PDF Version
February 25, 2019	KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 – KVD900 600 mg Provides >90% Inhibition of Plasma Kallikrein Within 30 Minutes of Dosing – – Single 600 mg Dose of KVD900 Provides Protection of HK Cleavage for at Least 10 Hours – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 25, 2019-- KalVista Pharmaceuticals, Inc....	Additional Formats PDF Version